Short-Term Treatment With Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects With Type 2 Diabetes Mellitus Who Have a Metabolic Syndrome and Normal Glucose Tolerance Without Changes in C-Reactive Protein or Fibrinogen . Clinics 2009, 64 (5), 415-420. https://doi.org/10.1590/S1807-59322009000500008.